Evidence map›Paper›PMID 34741343›Full record

ArticleAnnals of neurology2022

miR-146b Protects the Perinatal Brain against Microglia-Induced Hypomyelination.

Cindy Bokobza, Pooja Joshi, Anne-Laure Schang, Zsolt Csaba, Valérie Faivre, Amélie Montané, Anne Galland, Anouk Benmamar-Badel, Emmanuelle Bosher, Sophie Lebon and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Microglial activation is inhibited by selective anti-seizure medications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Preterm birth: A neuroinflammatory origin for metabolic diseases?Brain, behavior, & immunity - health · 2024
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 3 countries.

Cindy BokobzaUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Pooja JoshiUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Anne-Laure SchangUniversité de Paris, Centre de recherche en Epidémiologie et Statistiques, Inserm, Paris, France.
Zsolt CsabaUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Valérie FaivreUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Amélie MontanéUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Anne GallandUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Anouk Benmamar-BadelUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Emmanuelle BosherUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Sophie LebonUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Leslie SchwendimannUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Shyamala ManiUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Pascal DournaudUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Valerie BessonUniversité de Paris, Faculté de Pharmacie de Paris, UMR-S1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.
Bobbi FleissUniversité de Paris, NeuroDiderot, Inserm, Paris, France.
Pierre Gressens *Université de Paris, NeuroDiderot, Inserm, Paris, France.
Juliette Van Steenwinckel *Université de Paris, NeuroDiderot, Inserm, Paris, France.ORCID 0000-0003-3463-4856
Inserm · FRUniversité Paris Cité · FR

Funding

Agence Nationale de la Recherche Investissement d'Avenir -ANR-11-INBS-0011 NeurATRIERANET NEURON TRAINSEUR G.E.N.E #ANR-17-EURE-0013Fondation de FranceFondation des Gueules CasseesFondation Grace de MonacoFondation pour le Recherche MedicaleFondation Roger de SpoelberchGuy's & St Thomas' NHS Foundation TrustHorizon 2020 Framework Program of the European Union 874721/PREMSTEMInstitut National de la Sante et de la Recherche MedicaleUniversite Paris Diderot
6 · The paper itself

Abstract

objectivesIn the premature newborn, perinatal inflammation mediated by microglia contributes significantly to neurodevelopmental injuries including white matter injury (WMI). Brain inflammation alters development through neuroinflammatory processes mediated by activation of homeostatic microglia toward a pro-inflammatory and neurotoxic phenotype. Investigating immune regulators of microglial activation is crucial to find effective strategies to prevent and treat WMI.

methodsEx vivo microglial cultures and a mouse model of WMI induced by perinatal inflammation (interleukin-1-beta [IL-1β] and postnatal days 1-5) were used to uncover and elucidate the role of microRNA-146b-5p in microglial activation and WMI.

resultsA specific reduction in vivo in microglia of Dicer, a protein required for microRNAs maturation, reduces pro-inflammatory activation of microglia and prevents hypomyelination in our model of WMI. Microglial miRNome analysis in the WMI model identified miRNA-146b-5p as a candidate modulator of microglial activation. Ex vivo microglial cell culture treated with the pro-inflammatory stimulus lipopolysaccharide (LPS) led to overexpression of immunomodulatory miRNA-146b-5p but its drastic reduction in the microglial extracellular vesicles (EVs). To increase miRNA-146b-5p expression, we used a 3DNA nanocarrier to deliver synthetic miRNA-146b-5p specifically to microglia. Enhancing microglial miRNA-146b-5p overexpression significantly decreased LPS-induced activation, downregulated IRAK1, and restored miRNA-146b-5p levels in EVs. In our WMI model, 3DNA miRNA-146b-5p treatment significantly prevented microglial activation, hypomyelination, and cognitive defect induced by perinatal inflammation. INTERPRETATIONS: These findings support that miRNA-146b-5p is a major regulator of microglia phenotype and could be targeted to reduce the incidence and the severity of perinatal brain injuries and their long-term consequences. ANN NEUROL 2022;91:48-65.

Indexed as

AnimalsBrainMiceMicrogliaMicroRNAsNeurogenesisWhite MatterMicroRNAsMirn146 microRNA, mouse

Identifiers

PMID34741343
PMCPMC9298799
OpenAlexW3210529395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.